Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 1417    
Year : 2018  |  Volume : 148  |  Issue : 7  |  Page : 50-63

Dendritic cell engineering for selective targeting of female reproductive tract cancers

1 Department of Molecular Biology, ICMR-National Institute for Research in Environmental Health, Bhopal, India
2 Department of Biotechnology, All India Institute of Medical Sciences, New Delhi, India
3 School of Pharmacy & Technology Management, Narsee Monjee Institute of Management & Studies, Shirpur, India
4 Division of Reproductive Biology, Maternal & Child Health, Indian Council of Medical Research, New Delhi, India

Correspondence Address:
Dr Pradyumna Kumar Mishra
Department of Molecular Biology, ICMR-National Institute for Research in Environmental Health, Kamla Nehru Hospital Building (Gandhi Medical College Campus), Bhopal 462 001, Madhya Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijmr.IJMR_224_18

Rights and Permissions

Female reproductive tract cancers (FRCs) are considered as one of the most frequently occurring malignancies and a foremost cause of death among women. The late-stage diagnosis and limited clinical effectiveness of currently available mainstay therapies, primarily due to the developed drug resistance properties of tumour cells, further increase disease severity. In the past decade, dendritic cell (DC)-based immunotherapy has shown remarkable success and appeared as a feasible therapeutic alternative to treat several malignancies, including FRCs. Importantly, the clinical efficacy of this therapy is shown to be restricted by the established immunosuppressive tumour microenvironment. However, combining nanoengineered approaches can significantly assist DCs to overcome this tumour-induced immune tolerance. The prolonged release of nanoencapsulated tumour antigens helps improve the ability of DC-based therapeutics to selectively target and remove residual tumour cells. Incorporation of surface ligands and co-adjuvants may further aid DC targeting (in vivo) to overcome the issues associated with the short DC lifespan, immunosuppression and imprecise uptake. We herein briefly discuss the necessity and progress of DC-based therapeutics in FRCs. The review also sheds lights on the future challenges to design and develop clinically effective nanoparticles-DC combinations that can induce efficient anti-tumour immune responses and prolong patients' survival.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded203    
    Comments [Add]    

Recommend this journal